Map
We connect the record. Trials, approvals, patents, plants, prices and filings, resolved into one map. When a company changes its name or a molecule appears under three codes, we resolve it.
OutputThe Atlas
Media house · Life sciences · Built in India
India makes the world's medicine. It cannot see its own industry.
Origin43 maps, decodes and forecasts Indian biotech, from the public record most people never read.
Study 01 · In progress
Is India preventing disease, or only treating it?
01 — The scatter
Nothing in Indian biotech is secret. Almost all of it is unseen.
India's trial registry, drug regulator, patent office, price regulator and company registry all publish their records. None of them link to each other, and much of it sits in PDFs and portals built for compliance, not for reading.
02 — The trail
Follow one medicine through the public record.
The record exists. It is spread across registries, regulators, patent offices, gazettes and filings that were never built to talk to each other.
- 01Trial registryEntry
- Reg. no.
- CTRI/20XX/XX/XXXXXX
- Public title
- Sponsor
- Phase
- Phase
- Sites
- Status
A trial, in one registry.
- 02RegulatorPage 1 of 14Approved
An approval, in a scanned PDF.
03A patent, in another system.
- 04InspectionObservations
Observation 1
Observation 2
Observation 3
A factory, in an inspection letter.
- 05GazettePrice notice
Formulation Unit Ceiling ₹ 1 tab 1 tab 1 cap 1 ml A price, in a government gazette.
- 06Company filingsOne entityPharma Pvt LtdInc.LifesciencesRenamedBio LtdListed
A company, under three different names.
One molecule. Six places. No connection.
To answer a simple question (who is developing what, where, and how far along) someone has to stitch six separate systems together by hand. Most people never do, so most questions go unanswered.
The science is here. The map isn't.
03 — What scatter costs
01
Scatter is where mistakes hide.
An error in one filing is never checked against the others.
02
Where capital misprices.
Investors price Indian companies on headlines rather than the full record.
03
Where good science goes unnoticed.
Strong Indian research rarely travels beyond its own field.
04
Where bad actors go unchecked.
A problem spread across six systems is invisible in any single one.
04 — Our mission
We are mapping all of Indian biotech.
We read every public source, match the same company, molecule and site across all of them, and connect it into one record. Then we publish what that record shows: open data, explainers and studies.
One record.
05 — The work
Three verbs. Everything we publish does one of them.
Decode
We say what it means. The deals, the science, the money and the rules, explained in plain language, with every claim linked to the record it came from.
OutputExplainers
Forecast
We say what comes next. Trials hint at launches. Patents hint at competition. Inspections hint at shortages. Grants hint at the next wave of companies.
OutputStudies
06 — Where we stand
Most people look through one lens.
The truth sits where all three meet. That intersection is where Origin43 works: every story has to make sense economically, technically and on the record.
Economics
Who pays, who profits, and how money moves through Indian biotech: pricing, funding, exports and margins.
Technology
The science and tools that decide what's possible: modalities, platforms, manufacturing, and the shift from generics to discovery.
Inquiry
Close, evidence-first scrutiny of the record. We look at what doesn't add up and publish what we find, with the receipts.
07 — Origin43 Studies
We're starting with three questions.
Long-form studies built on the record. Each one ships with its data.
Study 01 · Preventive healthcareIn progress
Is India preventing disease, or only treating it?
We map vaccines, diagnostics and screening to show where the money and science are going, and where they aren't.
Study 02 · Drug discoveryIn progress
Is India discovering medicines, or only copying them?
We trace every novel molecule in Indian development, from lab to clinic, to measure how real the shift from generics is.
Study 03 · Competitive intelligenceIn progress
Who is actually winning Indian pharma?
We map head-to-head competition: who's ahead, who's crowded out, and where the white space is.
08 — How we work
- 01
We read everything.
Every public source, not a sample.
- 02
We cite everything.
Every claim links to the record it came from.
- 03
We answer to no sponsor.
Sponsors never see or shape what we publish.
- 04
We correct in public.
Mistakes are fixed on the page where they happened.
Somebody has to read the record. We do.
The Origin43 Brief: what moved in Indian biotech, what it means, and what we're watching next. Written for founders, investors, scientists and operators.